Chemomab Therapeutics Ltd. American Depositary Share
CMMB
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Last trade$1.65
Day change+$0.025 (+1.54%)
Day range$1.62 – $1.69
Volume133,921
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.04M
Price / earnings
—
Price / book
0.47×
Price / sales
—
EV / sales
—
EV / EBITDA
0.24×
Profitability
Earnings per share
-$3.89
Return on assets
-89.38%
Return on equity
-111.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.83×
Quick ratio
4.83×
Cash ratio
2.97×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CMMB, quarterly periods
Line item
Q1 FY2023 Mar 31, 2023
Q4 FY2022 Dec 31, 2022
Q3 FY2022 Sep 30, 2022
Q2 FY2022 Jun 30, 2022
Q1 FY2022 Mar 31, 2022
Q4 FY2021 Dec 31, 2021
Q3 FY2021 Sep 30, 2021
Q2 FY2021 Jun 30, 2021
Revenue
—
—
—
—
—
—
—
—
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
—
—
—
—
—
—
—
—
Selling, general and administrative
$2.16M
$2.75M
$2.89M
$3.34M
$2.58M
$2.64M
$1.4M
$1.45M
Research and development
$6.89M
$5.9M
$5.42M
$2.91M
$2.75M
$2.38M
$1.49M
$1.31M
Total operating expenses
$9.05M
$8.64M
$8.32M
$6.25M
$5.32M
$5.02M
$2.89M
$2.75M
Operating income
-$9.05M
-$8.64M
-$8.32M
-$6.25M
-$5.32M
-$5.02M
-$2.89M
-$2.75M
Interest expense
—
$380K
$237K
-$480K
—
-$12K
-$77K
-$17K
Income before taxes
-$8.73M
-$8.26M
-$8.08M
-$6.73M
-$5.1M
-$5.04M
-$2.97M
-$2.77M
Income taxes
$21K
$10K
$0
-$544K
$0
$0
$0
$0
Net income
-$8.75M
-$8.27M
-$8.08M
-$6.19M
-$5.1M
-$5.04M
-$2.97M
-$2.77M
Net income attributable to common shareholders
-$8.75M
-$8.27M
-$8.08M
-$6.19M
-$5.1M
-$5.04M
-$2.97M
-$2.77M
EBITDA
-$9.03M
-$8.64M
-$8.3M
-$6.24M
-$5.31M
-$5.02M
-$2.88M
-$2.75M
Basic earnings per share
-$0.16
-$0.14
-$0.14
-$0.11
-$0.09
-$0.09
-$0.05
-$0.05
Diluted earnings per share
-$0.16
-$0.14
-$0.14
-$0.11
-$0.09
-$0.09
-$0.05
-$0.05
Recent news
Company coverage with links to the original publishers.
Chemomab Therapeutics reported Q1 2026 financial results showing a net loss of $1.8 million and cash position of $8.0 million (runway through Q1 2027). The company presented new clinical data at major medical conferences demonstrating nebokitug's disease-modifying potential in primary sclerosing cholangitis (PSC) and potential benefits for PSC patients with co-existing inflammatory bowel disease (IBD). Multiple proteomic and gene expression analyses showed dose-dependent reductions in fibrosis and inflammatory biomarkers. The company continues advancing strategic partnership discussions for nebokitug.
Chemomab Therapeutics reported positive 2025 results highlighted by successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), establishing a clear pathway to potential regulatory approval based on a single Phase 3 trial. The company's Phase 2 SPRING trial data showed nebokitug was safe and well-tolerated with improvements in inflammation and fibrosis biomarkers. Cash position of $10.4 million is expected to fund operations through Q1 2027, with R&D expenses declining to $5.8 million for 2025 as the Phase 2 trial completed.
Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.
Chemomab Therapeutics reported positive Phase 2 results for its lead drug candidate CM-101 in primary sclerosing cholangitis, demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company plans to advance CM-101 to a Phase 3 trial and is in discussions with potential partners.
Chemomab Therapeutics, a clinical-stage biotechnology company, announced it will report its Q2 2024 financial results and provide a business update on August 21, 2024. The company is developing a monoclonal antibody, CM-101, to treat various fibro-inflammatory diseases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.